Focus on Optimized Dosing of Ibrutinib Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Welcome and Introduction to Vi3C

Amit Sanyal, MD: A Clinician’s Perspective

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Lymphoma

The ASCO Post Staff

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Feb

Today In Oncology

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Related Videos

Welcome and Introduction to Vi3C

Amit Sanyal, MD: A Clinician’s Perspective

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Adjuvant Durvalumab in Resected Early-Stage NSCLC

Ultrasound-Guided DOT May Reduce Unnecessary Breast Biopsies by Nearly 25

AACR Announces Fellows of the AACR Academy Class of 2026

Extended Endocrine Therapy in Premenopausal Patients With Node-Positive, Hormone Receptor–Positive Breast Cancer

Consensus Recommendations Developed for Use of Liquid Nitrogen Spray Cryotherapy in Barrett Esophagus Esophageal Cancer